Posted on

Largest psilocybin study continues to grow

COMPASS Pathways plc announces financial results and business highlights for the second quarter 2021

The world’s largest psilocybin therapy study on depression is approaching completion, and it’s even bigger than expected.

Compass Pathways (CMPS) announced that it’s close to completing its phase 2b trial on treatment-resistant depression, and expects to report the findings by the end of this year. So far, 233 patients have received COMP360 psilocybin therapy, exceeding the target of 216. The company also announced its Q2 financial highlights including $316.3 million in cash and equivalents as of June 30.

PDF of article

Posted on

Tripping harder in half the time

Mindset Pharma Announces Preclinical Results Demonstrating Superior Efficacy, Safety and Shorter Duration of Action Across Multiple Next Generation Psychedelic Drug Families

Is this novel compound superior to natural psilocybin?

Mindset Pharma (MSET) revealed preclinical research suggesting that its novel psilocybin/psilocin analogs are more effective and faster acting than psilocybin, making them ideal for use in clinical settings.

An in vitro study (a study on cells in a petri dish) showed that the novel compounds had 5-10 times the effect on serotonin 5-HT2A receptors as psilocybin, which was verified by testing on mice. The half-life of the compound was less than half of psilocybin’s, which would make psychedelic therapy sessions much more efficient.

PDF of article

Posted on

Going against the industry standard

Filament Health Is the First Public Company to be Issued a Patent for Extraction of Natural Psilocybin

Since natural psilocybin is typically expensive to extract, most companies create synthetic psilocybin, but not Filament Health (FH).

The Vancouver-based company developed an innovative technology that extracts and standardizes natural psilocybin to overcome crop-to-crop and flush-to-flush variability at a low cost. On Tuesday, Filament received a patent for the process, making it the first publicly traded company to receive a patent from the Canadian Intellectual Property Office for the extraction of natural psilocybin.

Posted on

Changing the way we digest medicine

PsiloThera Announces Launch of Quantum Technology Drug Development Program

PsiloThera Inc. launched a quantum technology drug development program that could change the way we digest supplements, medications and nutrients.

PsiloThera’s CEO claims that the program could significantly reduce drug development time and costs, and could improve dispensing issues and adverse effects of pharmaceuticals. The technology could also lead to advancements in energy-based nutrients and medication delivery systems. The company is focusing on treatments for depression, anxiety, PTSD, eating disorders, addiction, dementia, and autism (to name a few), and is currently crowdsourcing funds through a Start Engine campaign.

 

Posted on

The company that’s about to double in size

Novamind Opens 5th Location Specialized in Integrative Psychiatry for Patients with Treatment-Resistant Conditions

From 4 to 8 clinics in 1 month!

Novamind (NM) is on track to double its network of clinics over the next few weeks, with the goal of expanding access to psychedelic-assisted therapy if granted FDA approval. The company opened its fifth clinic in Utah today and will open three more in the state by September before expanding to other states by the end of the year. The clinics will serve as referral centers for patients with treatment-resistant conditions including depression, eating disorders, PTSD and OCD.

Posted on

Snorting shrooms?

atai Life Sciences launches InnarisBio, in partnership with the University of Queensland, with the aim to develop a more effective nose-to-brain delivery method for atai’s platform of mental health therapeutic programs

PsiloThera isn’t the only company changing the way we take drugs.

atai Life Sciences (ATAI) is partnering with the University of Queensland to commercialize a new nose-to-brain drug delivery technology for psychedelic and non-psychedelic compounds. The nasal method has potential to be more effective at treating central nervous system (CNS) disorders than oral administration because it bypasses the blood-brain barrier that can restrict the entry of therapeutic agents. The nose-to-brain technology may require a lower dose than oral methods and may reduce dosing frequency too  –  plus its non-invasive and painless.

Posted on

A psychedelics company’s new meditation device that could save the planet

Red Light Holland Files New Patent: Technology and Devices for Monitoring Information and Influencing Behavior Involving Carbon Dioxide Emissions

Red Light Holland (TRIP) filed a patent for a new (very strange) device that might inspire the psychedelic community to be more eco-friendly.

The devices, called Wisdom Truffles, are smart lights that provide real-time data on CO2 emissions from local electricity grids, plus suggestions for reducing emissions. Oh, and they can help you meditate too.

Three models are currently under development, including a handheld meditation aid that can track physiological changes while meditating or microdosing, as well as a life-sized figurine that uses AI to create interactive experiences based on dances and stretches. Don’t worry, we’re just as confused as you… Check out the devices here.

PDF of article

Posted on

Can shrooms help with weight loss?

Expert: Psilocybin Treatment May Support Patients With Obesity Who Have Tried Everything, Need Further Support

Experts think magic mushrooms could be the key to creating healthier habits.

In pre-clinical trials, both low and high doses of psilocybin caused rats to gain less weight when given unlimited access to food. A consultant to NeonMind Inc. (NEON) stated that psilocybin can cause a decrease in hunger by targeting 5-HT2C receptors and can give patients a sense of well-being. He explains that using psilocybin to enhance psychotherapy may be able to instill long lasting behaviour changes such as improved diet and increased exercise.

This week, NeonMind completed an integrated drug development plan for NEO-001, its high dose psilocybin treatment for weight management, which is expected to be researched in a Phase 1/2 proof-of-concept study in early 2022.

PDF of article 1

PDF of article 2